Coronaviruses have long infected humans, yet none caused the same devastation as SARS-CoV-2 has (Li et al., 2020; Huang et al., 2020). For instance, a virulent and lethal coronavirus, SARS-CoV-1, caused a much smaller outbreak in 2002–2003 (Lee et al., 2003; Peiris et al., 2003). Numerous human coronaviruses such as NL63-CoV cause common colds annually (Fouchier et al., 2004; van der Hoek et al., 2004). With an intermediate virulence, SARS-CoV-2 causes a fatality rate that is significantly lower than that of SARS-CoV-1, but much higher than that of NL63-CoV. Because of its intermediate virulence, SARS-CoV-2 carriers show clinical signs that facilitate the spread of the virus: they may develop mild or no symptoms, experience delayed onset of symptoms, develop low levels of neutralizing antibodies, or endure prolonged virus shedding period (Wu et al., 2020; Zhou et al., 2020; Wölfel et al., 2020; Gao et al., 2020; Kronbichler et al., 2020). These features contribute to the wide spread of SARS-CoV-2 and severe health outcomes, triggering a global COVID-19 pandemic that was unprecedented in the era of modern medicine. Understanding the molecular determinants of COVID-19 is crucial for comprehending the recent pandemic and preventing future ones.

SARS-CoV-2 spike protein played a central role in the COVID-19 pandemic. It guides viral entry into host cells and is also a major target for the host immune responses (Du et al., 2009; Li, 2016). On newly packaged virus particles, the trimeric spike protein has a pre-fusion structure in which three receptor-binding S1 subunits sit on top of a trimeric membrane-fusion S2 stalk (Figure 1A). During viral entry, a receptor-binding domain (RBD) in S1 binds to a receptor on host cell surface for viral attachment and S2 switches to a post-fusion structure for the fusion of viral and host membranes (Li, 2016; Li, 2015). SARS-CoV-2, SARS-CoV-1, and NL63-CoV can all use ACE2 as their receptor (Li et al., 2003; Li et al., 2005; Shang et al., 2020c; Wan et al., 2020a; Wu et al., 2009). Early in the pandemic, we described three distinct characteristics of SARS-CoV-2 spike: its exceptional binding affinity for human ACE2, its proteolytic activation by human protease furin, and its existence as a mixture of two conformations: an open conformation in which the RBD is exposed and accessible to ACE2 and a closed conformation in which the RBD is buried and inaccessible to ACE2 (Shang et al., 2020b). While much has been learned about the first two characteristics (Shang et al., 2020c; Lan et al., 2020; Essalmani et al., 2022; Peacock et al., 2021; Geng et al., 2022; Zhang et al., 2023), the third still remains poorly understood. Interestingly, SARS-CoV-1 spike is predominantly in the open conformation, whereas NL63-CoV spike remains closed (Walls et al., 2016; Wrobel et al., 2020; Gui et al., 2017). Thus, two key questions arise: what molecular switches regulate the conformation of coronavirus spikes and how do the conformational changes influence coronaviruses’ infectivity and host immune responses?

Figure 1

Download asset Open asset

In this study, we used cryo-EM and biochemical approaches to identify spike residue 417 as a molecular switch that regulates the conformation of SARS-CoV-2 spike. We delved deeper into how this molecular switch affects receptor binding, viral entry, and immune evasion by SARS-CoV-2. Through regulation of its spike’s conformations, SARS-CoV-2 may have struck a balance between infection potency and immune evasiveness.

To understand the molecular mechanism that controls the spike’s switching between open and closed conformations, we compared the sequences of SARS-CoV-2 and SARS-CoV-1 spikes in the context of their tertiary structures. We identified residue 417 as potentially a key difference between the two spikes: in the closed SARS-CoV-2 trimeric spike, Lys417 in the RBD from one spike subunit forms a hydrogen bond with the main chain of Asn370 in the RBD from another spike subunit, stabilizing the RBDs in the closed conformation (Walls et al., 2020; Figure 1B). In SARS-CoV-1 spike, however, this residue becomes a valine (Li et al., 2005; Shang et al., 2020a; Figure 1C), losing its capability to form the hydrogen bond with another spike subunit and potentially destabilizing the closed conformation of the spike. Thus, we hypothesized that a K417V mutation causes more SARS-CoV-2 spike molecules to take the open conformation. To test this hypothesis, we investigated the impact of the K417V mutation on the structure and function of SARS-CoV-2 spike using a combination of cryo-EM and biochemical approaches.

To examine how the K417V mutation affects the conformation of SARS-CoV-2 spike, we performed cryo-EM analysis of the RBD conformation of SARS-CoV-2 spike ectodomain containing either Lys417 or Val417. To this end, we introduced the K417V mutation into SARS-CoV-2 spike ectodomain and purified both versions of the protein: K417-spike containing Lys417 and V417-spike containing Val417. Due to the lack of the transmembrane anchor, the recombinant spike ectodomain was intrinsically unstable. To stabilize the recombinant spike ectodomain, we introduced six proline mutations into its S2 subunit to lock up its pre-fusion structure, introduced mutations to its furin motif to prevent it from being cleaved during molecular maturation, and added a C-terminal foldon tag to facilitate its trimerization (Shang et al., 2020b; Hsieh et al., 2020; Ye et al., 2022). We successfully obtained the stabilized K417-spike and V417-spike and collected cryo-EM data on both proteins (Figure 2—figure supplements 1 and 2; Supplementary file 1). For the K417-spike, 55% of the molecules were in the closed conformation with all three RBDs down, whereas the rest of the molecules (45%) were in the open conformation with one RBD up and two RBDs down (Figure 2A and B). In contrast, for the V417-spike, these numbers became 32 and 68% for the closed and open conformations, respectively (Figure 2C and D). Therefore, the K417V mutation allowed more SARS-CoV-2 spike molecules to take the open conformation, confirming our hypothesis.

Figure 2 with 2 supplements see all

Download asset Open asset

While the above cryo-EM approach examined the conformation of recombinant spike ectodomain, we further examined the impact of the K417V mutation on the membrane-anchored and full-length SARS-CoV-2 spike that do not contain S2 or furin motif mutations. It has been shown that ACE2 only binds to the standing-up RBD in the open spike (Gui et al., 2017; Ye et al., 2021), suggesting that the open spike conformation is necessary for ACE2 binding. Hence, we characterized the capabilities of K417-spike and V417-spike in binding ACE2. First, we expressed the K417-spike and V417-spike on human cell surface and performed a protein pull-down assay using recombinant human ACE2 as the bait and the cell-surface-anchored spikes as the target (Figure 3A). For cross-validation, both His-tagged ACE2 and Fc-tagged ACE2 were used. We previously showed that this pull-down assay is a reliable method to probe the RBD conformation of cell-surface-anchored spikes, with higher pull-down levels of spikes associated with more spike molecules in the open conformation (Shang et al., 2020b). Western blot analysis showed that some of the spike molecules had been cleaved at the S1/S2 boundary, confirming the intact furin motif (Figure 3A). The pull-down result showed that, compared to K417-spike, more V417-spike molecules had been pulled down by ACE2, suggesting that V417-spike had an increased probability of binding to ACE2 (Figure 3A). Second, we conducted a flow cytometry assay to detect the interactions between recombinant human ACE2 and cell-surface-anchored spikes (Figure 3B, Figure 3—figure supplement 1). Here, two versions of both K417-spike and V417-spike were used: one containing the intact furin motif and the other the inactivated furin motif. The result showed that V417-spike binds to ACE2 better than does K417-spike, no matter whether the furin motif was intact or inactivated (Figure 3B, Figure 3—figure supplement 1). Taken together, both protein pull-down and flow cytometry results reveal that the K417V mutation allowed more SARS-CoV-2 spike molecules to take the open conformation, confirming the cryo-EM data and our hypothesis.

Figure 3 with 1 supplement see all

Download asset Open asset

Figure 3—source data 1

Raw image for Figure 3A.

https://cdn.elifesciences.org/articles/74060/elife-74060-fig3-data1-v3.pptx

Download elife-74060-fig3-data1-v3.pptx

Figure 3—source data 2

Numerical data for Figure 3B.

https://cdn.elifesciences.org/articles/74060/elife-74060-fig3-data2-v3.xlsx

Download elife-74060-fig3-data2-v3.xlsx

Figure 3—source data 3

Numerical data for Figure 3C.

https://cdn.elifesciences.org/articles/74060/elife-74060-fig3-data3-v3.pptx

Download elife-74060-fig3-data3-v3.pptx

Figure 3—source data 4

Raw image for Figure 3C.

https://cdn.elifesciences.org/articles/74060/elife-74060-fig3-data4-v3.xlsx

Download elife-74060-fig3-data4-v3.xlsx

To understand the role of the spike’s conformations in viral entry, we conducted a pseudovirus entry assay. Specifically, retroviruses pseudotyped with SARS-CoV-2 spike (i.e., SARS-CoV-2 pseudoviruses) were evaluated for their capability to enter ACE2-expressing human cells. Two types of SARS-CoV-2 pseudoviruses were used: the K417-spike-charged pseudoviruses (i.e., K417-pseudoviruses) and V417-spike-charged pseudoviruses (V417-pseudoviruses). Both types of pseudoviruses contain the furin motif in their spike. Western blot analysis showed that some of the spike molecules had been cleaved at the S1/S2 boundary when expressed on pseudovirus surface, confirming the intact furin motif (Figure 3C). The pseudovirus entry result showed that V417-pseudoviruses entered cells more efficiently than did K417-pseudoviruses (Figure 3C). Thus, the open spike enhances not only ACE2 binding, but also viral entry.

To understand the role of the spike’s conformation in immune evasion, we analyzed how neutralizing antibodies recognize the RBD in the context of the trimeric spike protein. To this end, we summarized the binding sites of known neutralizing antibodies on the RBD (Figure 4A). These neutralizing antibodies were discovered individually from COVID-19 patients. They generally recognize five groups of neutralizing epitopes on the RBD (Starr et al., 2021; Dussupt et al., 2021; Scheid et al., 2021; Fedry et al., 2021). Three groups of these RBD epitopes are only accessible to neutralizing antibodies when the spike adopts the open conformation (Starr et al., 2021; Dussupt et al., 2021). In comparison, the other two groups of RBD epitopes are accessible to neutralizing antibodies when the spike adopts either open or closed conformation (Scheid et al., 2021; Fedry et al., 2021). In addition to the above conventional antibodies, neutralizing nanobodies (which are single-domain antibodies derived from camelid animals) have also been discovered to target the RBD. Because of their single-domain structure, nanobodies are known to bind to cryptic epitopes on viral targets. We recently discovered four RBD-targeting nanobodies, named Nanosota-1, -2, -3, and -4 (Ye et al., 2021; Ye et al., 2023; Figure 4B). Among them, Nanosota-2 binds to an epitope on the RBD that almost completely overlaps with the ACE2-binding site. Interestingly, the Nanosota-2 epitope is only accessible to Nanosota-2 when the RBD is in the open conformation (Ye et al., 2023). This result suggests that even with the small size of nanobodies, SARS-CoV-2 may be able to evade some of them when its spike is in the closed conformation. Overall, these epitope-based analyses reveal that SARS-CoV-2 spike in the closed conformation can evade significant amounts of neutralizing antibodies, confirming our previous hypothesis that the closed conformation of the spike is a viral strategy for immune evasion (Shang et al., 2020b).

Figure 4

Download asset Open asset

To further understand the role of the K417 mutation in ACE2 binding and viral entry, we examined how the K417 mutation directly affects the RBD’s binding affinity for ACE2 instead of the trimeric spike’s. The structure of SARS-CoV-2 RBD complexed with human ACE2 showed that Lys417 in SARS-CoV-2 RBD is directly involved in ACE2 binding by forming a salt bridge with Asp30 in human ACE2 (Lan et al., 2020; Figure 5A). In contrast, the corresponding residue in SARS-CoV-1 RBD is a valine that does not form any direct interactions with human ACE2 (Li et al., 2005; Figure 5B). Here, we introduced the K417V mutation to SARS-CoV-2 RBD and investigated the binding interactions between the recombinant SARS-CoV-2 RBD (containing either Lys417 or Val417) and cell-surface-anchored human ACE2 using flow cytometry. The result showed that the K417V mutation reduced the RBD’s binding affinity for ACE2 (Figure 5C, Figure 5—figure supplement 1). Thus, the K417V mutation has contrasting effects on the RBD and the trimeric spike in terms of ACE2 binding: it weakens the RBD’s ability to bind to ACE2 by eliminating a favorable interaction at the RBD/ACE2 interface, but it increases the trimeric spike’s probability of binding to ACE2 by enabling more spike molecules to assume the open conformation.

Figure 5 with 1 supplement see all

Download asset Open asset

Figure 5—source data 1

Numerical data for Figure 5C.

https://cdn.elifesciences.org/articles/74060/elife-74060-fig5-data1-v3.zip

Download elife-74060-fig5-data1-v3.zip

To summarize, we identified and investigated a molecular switch regulating the conformation of SARS-CoV-2 spike protein. We used multiple approaches: cryo-EM study of recombinant spike ectodomains, biochemical investigation of cell-surface-anchored full-length and wild-type spikes, spike-mediated pseudovirus entry, and structural analysis of neutralizing antibody/nanobody epitopes. To date, several other studies also investigated the conformation of SARS-CoV-2 spike using cryo-EM (Wrobel et al., 2020; Walls et al., 2020; Ke et al., 2020; Xiong et al., 2020; Cai et al., 2020; Benton et al., 2021), some of which gave different ratios of open and closed spikes probably due to differences in sample preparations and/or protein constructions. In this study, the two spike constructs only differ at residue 417 and the two spike samples were prepared using the same procedure. Importantly, our cryo-EM analysis is consistent with our extensive biochemical and functional approaches. These varied experimental methods complement one another, making this study one of the most thorough in examining the conformation of SARS-CoV-2 spike.

We previously described a unique feature of the prototypic SARS-CoV-2 spike protein: it is present as a mixture of open and closed conformations (Shang et al., 2020b). Building on this discovery, this study demonstrates that the conformation of SARS-CoV-2 spike is regulated, at least in part, by a structural switch. Additionally, this research sheds light on the roles of the conformational changes in the spike’s functions. These findings have implications for the structure, function, and evolution of coronavirus spikes, as well as for the present and potential future coronavirus infections.

How has SARS-CoV-2 spike evolved to reach a balance of open and closed conformations? Through comparative studies of SARS-CoV-2 and SARS-CoV-1 spikes, we identified a molecular switch, RBD residue 417, that regulates the conformational changes of SARS-CoV-2 spike. Lys417 in the closed SARS-CoV-2 spike forms a hydrogen bond with another spike subunit, stabilizing the closed spike. In contrast, Val417 in SARS-CoV-1 spike cannot form such a hydrogen bond with another spike subunit, unable to stabilize the closed spike. When we introduced the K417V mutation to SARS-CoV-2 spike, more spike molecules turned open. Interestingly, Lys417 in the RBD of SARS-CoV-2 spike also directly interacts with ACE2, and we showed that the K417V mutation reduced the RBD’s binding affinity for ACE2. Hence, the K417V mutation has opposing effects on the RBD and the spike for their binding to ACE2. The net outcomes of the K417 mutation are to enhance the spike’s overall binding to ACE2 and the spike’s capability to mediate viral entry.

Besides residue 417, there are likely other molecular factors that influence the opening and closing of SARS-CoV-2 spike. Studies have shown that N-linked glycans on the spike and fatty acids bound to the spike both play a role in regulating its conformation (Toelzer et al., 2020; Sztain et al., 2021). As for protein-based factors, a D614G mutation that emerged later in the pandemic caused SARS-CoV-2 spike to favor the open conformation (Yurkovetskiy et al., 2020; Ozono et al., 2021). Furthermore, our earlier research indicated that three lysine residues kept SARS-CoV-2 Omicron spike in the open conformation (Ye et al., 2022). It is worth noting that residue 417 itself has been a mutational hotspot in SARS-CoV-2 spike; in some pre-Omicron variants, it changed to either asparagine or threonine, and in most Omicron subvariants, it became asparagine (Figure 1C). Given that the side chains of Asn417 and Thr417 might be too short to form a direct interaction with another spike subunit, the mutations at residue 417 could have influenced the conformation of the spike in subsequent SARS-CoV-2 variants. Nevertheless, this study focuses on prototypic SARS-CoV-2, offering comprehensive structural, biochemical, and functional data that pinpoint residue 417 as a key determinant in regulating the conformation of the prototypic spike. The molecular switch at residue 417 could have been a factor in the onset of the COVID-19 pandemic, as discussed below.

How does the conformation of SARS-CoV-2 spike influence both viral entry and immune evasiveness? Our study shows that, compared to its closed form, the open spike is more effective at binding to ACE2 and facilitating viral entry. This could enhance SARS-CoV-2’s ability to infect and spread among humans. We also found that certain epitopes on the RBD are accessible only in the open spike, allowing them to be targeted by neutralizing conventional antibodies and even compact single-domain nanobodies. This suggests the virus can efficiently evade hosts' immune defenses. The virus' ability to switch between open and closed spike conformations may be key to its balance of infectiousness and evasion of immunity. This delicate balance might explain the often mild symptoms and subdued, delayed immune reactions observed in SARS-CoV-2 carriers. In comparison, SARS-CoV-1 spike predominantly assumes the open conformation (89% open and 11% closed) (Gui et al., 2017), potentially leading to more pronounced symptoms and quicker, stronger immune reactions in those infected. Conversely, NL63-CoV spike remains closed (100% closed) (Walls et al., 2016), possibly resulting in even milder symptoms and more muted immune responses. Therefore, SARS-CoV-2’s blend of infectiousness and evasive abilities, differing from both the highly pathogenic SARS-CoV-1 and the milder NL63-CoV, might be a factor in its widespread transmission.

To summarize, Lys417 in SARS-CoV-2 spike aids in keeping the spike closed, potentially hindering ACE2 binding and viral entry, but providing an edge in immune evasion. Simultaneously, Lys417’s direct interaction with human ACE2 boosts ACE2 binding and viral entry, counteracting the limitations of the closed spike. This interesting mechanism helps SARS-CoV-2 maintain a delicate balance between infectiousness and evading host immune response.

All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 3 and 5. The atomic models and corresponding cryo-EM density maps have been deposited into the PDB and the Electron Microscopy Data Bank, respectively, with accession numbers PDB 8UUL and EMD-42589 (prototypic SARS-CoV-2 spike containing Lys417 in the closed conformation), PDB 8UUM and EMD-42590 (prototypic SARS-CoV-2 spike containing Lys417 in the open conformation), PDB 8UUN and EMD-42591 (prototypic SARS-CoV-2 spike containing Val417 in the closed conformation), and PDB 8UUO and EMD-42592 (prototypic SARS-CoV-2 spike containing Val417 in the open conformation).

1. 1. Li F

   (2023) RCSB Protein Data Bank

   ID 8UUL. Prototypic SARS-CoV-2 spike containing Lys417 in the closed conformation.

   https://www.rcsb.org/structure/8UUL
2. 1. Li F

   (2023) Electron Microscopy Data Bank

   ID EMD-42589. Prototypic SARS-CoV-2 spike containing Lys417 in the closed conformation.

   https://www.ebi.ac.uk/emdb/EMD-42589
3. 1. Li F

   (2023) RCSB Protein Data Bank

   ID 8UUM. Prototypic SARS-CoV-2 spike containing Lys417 in the open conformation.

   https://www.rcsb.org/structure/8UUM
4. 1. Li F

   (2023) Electron Microscopy Data Bank

   ID EMD-42590. Prototypic SARS-CoV-2 spike containing Lys417 in the open conformation.

   https://www.ebi.ac.uk/emdb/EMD-42590
5. 1. Li F

   (2023) RCSB Protein Data Bank

   ID 8UUN. Prototypic SARS-CoV-2 spike containing Val417 in the closed conformation.

   https://www.rcsb.org/structure/8UUN
6. 1. Li F

   (2023) Electron Microscopy Data Bank

   ID EMD-42591. Prototypic SARS-CoV-2 spike containing Val417 in the closed conformation.

   https://www.ebi.ac.uk/emdb/EMD-42591
7. 1. Li F

   (2023) RCSB Protein Data Bank

   ID 8UUO. Prototypic SARS-CoV-2 spike containing Val417 in the open conformation.

   https://www.rcsb.org/structure/8UUO
8. 1. Li F

   (2023) Electron Microscopy Data Bank

   ID EMD-42592. Prototypic SARS-CoV-2 spike containing Val417 in the open conformation.

   https://www.ebi.ac.uk/emdb/EMD-42592

1. 1. Adams PD
   2. Afonine PV
   3. Bunkóczi G
   4. Chen VB
   5. Davis IW
   6. Echols N
   7. Headd JJ
   8. Hung LW
   9. Kapral GJ
   10. Grosse-Kunstleve RW
   11. McCoy AJ
   12. Moriarty NW
   13. Oeffner R
   14. Read RJ
   15. Richardson DC
   16. Richardson JS
   17. Terwilliger TC
   18. Zwart PH

   (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution

   Acta Crystallographica. Section D, Biological Crystallography 66:213–221.

   https://doi.org/10.1107/S0907444909052925

   • PubMed
   • Google Scholar
2. 1. Benton DJ
   2. Wrobel AG
   3. Roustan C
   4. Borg A
   5. Xu P
   6. Martin SR
   7. Rosenthal PB
   8. Skehel JJ
   9. Gamblin SJ

   (2021) The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2

   PNAS 118:e2022586118.

   https://doi.org/10.1073/pnas.2022586118

   • PubMed
   • Google Scholar
3. 1. Cai Y
   2. Zhang J
   3. Xiao T
   4. Peng H
   5. Sterling SM
   6. Walsh RM
   7. Rawson S
   8. Rits-Volloch S
   9. Chen B

   (2020) Distinct conformational states of SARS-CoV-2 spike protein

   Science 369:1586–1592.

   https://doi.org/10.1126/science.abd4251

   • PubMed
   • Google Scholar
4. 1. Chen VB
   2. Arendall WB
   3. Headd JJ
   4. Keedy DA
   5. Immormino RM
   6. Kapral GJ
   7. Murray LW
   8. Richardson JS
   9. Richardson DC

   (2010) MolProbity: all-atom structure validation for macromolecular crystallography

   Acta Crystallographica. Section D, Biological Crystallography 66:12–21.

   https://doi.org/10.1107/S0907444909042073

   • PubMed
   • Google Scholar
5. 1. Du L
   2. He Y
   3. Zhou Y
   4. Liu S
   5. Zheng BJ
   6. Jiang S

   (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development

   Nature Reviews. Microbiology 7:226–236.

   https://doi.org/10.1038/nrmicro2090

   • PubMed
   • Google Scholar
6. 1. Dussupt V
   2. Sankhala RS
   3. Mendez-Rivera L
   4. Townsley SM
   5. Schmidt F
   6. Wieczorek L
   7. Lal KG
   8. Donofrio GC
   9. Tran U
   10. Jackson ND
   11. Zaky WI
   12. Zemil M
   13. Tritsch SR
   14. Chen WH
   15. Martinez EJ
   16. Ahmed A
   17. Choe M
   18. Chang WC
   19. Hajduczki A
   20. Jian N
   21. Peterson CE
   22. Rees PA
   23. Rutkowska M
   24. Slike BM
   25. Selverian CN
   26. Swafford I
   27. Teng IT
   28. Thomas PV
   29. Zhou T
   30. Smith CJ
   31. Currier JR
   32. Kwong PD
   33. Rolland M
   34. Davidson E
   35. Doranz BJ
   36. Mores CN
   37. Hatziioannou T
   38. Reiley WW
   39. Bieniasz PD
   40. Paquin-Proulx D
   41. Gromowski GD
   42. Polonis VR
   43. Michael NL
   44. Modjarrad K
   45. Joyce MG
   46. Krebs SJ

   (2021) Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

   Nature Immunology 22:1503–1514.

   https://doi.org/10.1038/s41590-021-01068-z

   • PubMed
   • Google Scholar
7. 1. Emsley P
   2. Cowtan K

   (2004) Coot: model-building tools for molecular graphics

   Acta Crystallographica. Section D, Biological Crystallography 60:2126–2132.

   https://doi.org/10.1107/S0907444904019158

   • PubMed
   • Google Scholar
8. 1. Essalmani R
   2. Jain J
   3. Susan-Resiga D
   4. Andréo U
   5. Evagelidis A
   6. Derbali RM
   7. Huynh DN
   8. Dallaire F
   9. Laporte M
   10. Delpal A
   11. Sutto-Ortiz P
   12. Coutard B
   13. Mapa C
   14. Wilcoxen K
   15. Decroly E
   16. Nq Pham T
   17. Cohen ÉA
   18. Seidah NG

   (2022) Distinctive roles of furin and TMPRSS2 in SARS-CoV-2 infectivity

   Journal of Virology 96:e0012822.

   https://doi.org/10.1128/jvi.00128-22

   • PubMed
   • Google Scholar
9. 1. Fedry J
   2. Hurdiss DL
   3. Wang C
   4. Li W
   5. Obal G
   6. Drulyte I
   7. Du W
   8. Howes SC
   9. van Kuppeveld FJM
   10. Förster F
   11. Bosch BJ

   (2021) Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11

   Science Advances 7:eabf5632.

   https://doi.org/10.1126/sciadv.abf5632

   • PubMed
   • Google Scholar
10. 1. Fouchier RAM
    2. Hartwig NG
    3. Bestebroer TM
    4. Niemeyer B
    5. de Jong JC
    6. Simon JH
    7. Osterhaus A

    (2004) A previously undescribed coronavirus associated with respiratory disease in humans

    PNAS 101:6212–6216.

    https://doi.org/10.1073/pnas.0400762101

    • PubMed
    • Google Scholar
11. 1. Gao M
    2. Yang L
    3. Chen X
    4. Deng Y
    5. Yang S
    6. Xu H
    7. Chen Z
    8. Gao X

    (2020) A study on infectivity of asymptomatic SARS-CoV-2 carriers

    Respiratory Medicine 169:106026.

    https://doi.org/10.1016/j.rmed.2020.106026

    • PubMed
    • Google Scholar
12. 1. Geng Q
    2. Tai W
    3. Baxter VK
    4. Shi J
    5. Wan Y
    6. Zhang X
    7. Montgomery SA
    8. Taft-Benz SA
    9. Anderson EJ
    10. Knight AC
    11. Dinnon KH
    12. Leist SR
    13. Baric RS
    14. Shang J
    15. Hong SW
    16. Drelich A
    17. Tseng CTK
    18. Jenkins M
    19. Heise M
    20. Du L
    21. Li F

    (2021) Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection

    PLOS Pathogens 17:e1009897.

    https://doi.org/10.1371/journal.ppat.1009897

    • PubMed
    • Google Scholar
13. 1. Geng Q
    2. Shi K
    3. Ye G
    4. Zhang W
    5. Aihara H
    6. Li F

    (2022) Structural basis for human receptor recognition by SARS-CoV-2 Omicron Variant BA.1

    Journal of Virology 96:e0024922.

    https://doi.org/10.1128/jvi.00249-22

    • PubMed
    • Google Scholar
14. 1. Goddard TD
    2. Huang CC
    3. Meng EC
    4. Pettersen EF
    5. Couch GS
    6. Morris JH
    7. Ferrin TE

    (2018) UCSF ChimeraX: Meeting modern challenges in visualization and analysis

    Protein Science 27:14–25.

    https://doi.org/10.1002/pro.3235

    • PubMed
    • Google Scholar
15. 1. Gui M
    2. Song W
    3. Zhou H
    4. Xu J
    5. Chen S
    6. Xiang Y
    7. Wang X

    (2017) Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding

    Cell Research 27:119–129.

    https://doi.org/10.1038/cr.2016.152

    • PubMed
    • Google Scholar
16. 1. Hsieh CL
    2. Goldsmith JA
    3. Schaub JM
    4. DiVenere AM
    5. Kuo HC
    6. Javanmardi K
    7. Le KC
    8. Wrapp D
    9. Lee AG
    10. Liu Y
    11. Chou CW
    12. Byrne PO
    13. Hjorth CK
    14. Johnson NV
    15. Ludes-Meyers J
    16. Nguyen AW
    17. Park J
    18. Wang N
    19. Amengor D
    20. Lavinder JJ
    21. Ippolito GC
    22. Maynard JA
    23. Finkelstein IJ
    24. McLellan JS

    (2020) Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

    Science 369:1501–1505.

    https://doi.org/10.1126/science.abd0826

    • PubMed
    • Google Scholar
17. 1. Huang C
    2. Wang Y
    3. Li X
    4. Ren L
    5. Zhao J
    6. Hu Y
    7. Zhang L
    8. Fan G
    9. Xu J
    10. Gu X
    11. Cheng Z
    12. Yu T
    13. Xia J
    14. Wei Y
    15. Wu W
    16. Xie X
    17. Yin W
    18. Li H
    19. Liu M
    20. Xiao Y
    21. Gao H
    22. Guo L
    23. Xie J
    24. Wang G
    25. Jiang R
    26. Gao Z
    27. Jin Q
    28. Wang J
    29. Cao B

    (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

    Lancet 395:497–506.

    https://doi.org/10.1016/S0140-6736(20)30183-5

    • PubMed
    • Google Scholar
18. 1. Ke Z
    2. Oton J
    3. Qu K
    4. Cortese M
    5. Zila V
    6. McKeane L
    7. Nakane T
    8. Zivanov J
    9. Neufeldt CJ
    10. Cerikan B
    11. Lu JM
    12. Peukes J
    13. Xiong X
    14. Kräusslich HG
    15. Scheres SHW
    16. Bartenschlager R
    17. Briggs JAG

    (2020) Structures and distributions of SARS-CoV-2 spike proteins on intact virions

    Nature 588:498–502.

    https://doi.org/10.1038/s41586-020-2665-2

    • PubMed
    • Google Scholar
19. 1. Kronbichler A
    2. Kresse D
    3. Yoon S
    4. Lee KH
    5. Effenberger M
    6. Shin JI

    (2020) Asymptomatic patients as A source of COVID-19 infections: a systematic review and meta-analysis

    International Journal of Infectious Diseases 98:180–186.

    https://doi.org/10.1016/j.ijid.2020.06.052

    • PubMed
    • Google Scholar
20. 1. Lan J
    2. Ge J
    3. Yu J
    4. Shan S
    5. Zhou H
    6. Fan S
    7. Zhang Q
    8. Shi X
    9. Wang Q
    10. Zhang L
    11. Wang X

    (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

    Nature 581:215–220.

    https://doi.org/10.1038/s41586-020-2180-5

    • PubMed
    • Google Scholar
21. 1. Lee N
    2. Hui D
    3. Wu A
    4. Chan P
    5. Cameron P
    6. Joynt GM
    7. Ahuja A
    8. Yung MY
    9. Leung CB
    10. To KF
    11. Lui SF
    12. Szeto CC
    13. Chung S
    14. Sung JJY

    (2003) A major outbreak of severe acute respiratory syndrome in Hong Kong

    The New England Journal of Medicine 348:1986–1994.

    https://doi.org/10.1056/NEJMoa030685

    • PubMed
    • Google Scholar
22. 1. Li W
    2. Moore MJ
    3. Vasilieva N
    4. Sui J
    5. Wong SK
    6. Berne MA
    7. Somasundaran M
    8. Sullivan JL
    9. Luzuriaga K
    10. Greenough TC
    11. Choe H
    12. Farzan M

    (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

    Nature 426:450–454.

    https://doi.org/10.1038/nature02145

    • Google Scholar
23. 1. Li F
    2. Li W
    3. Farzan M
    4. Harrison SC

    (2005) Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

    Science 309:1864–1868.

    https://doi.org/10.1126/science.1116480

    • PubMed
    • Google Scholar
24. 1. Li F

    (2015) Receptor recognition mechanisms of coronaviruses: a decade of structural studies

    Journal of Virology 89:1954–1964.

    https://doi.org/10.1128/JVI.02615-14

    • PubMed
    • Google Scholar
25. 1. Li F

    (2016) Structure, function, and evolution of coronavirus spike proteins

    Annual Review of Virology 3:237–261.

    https://doi.org/10.1146/annurev-virology-110615-042301

    • PubMed
    • Google Scholar
26. 1. Li Q
    2. Guan X
    3. Wu P
    4. Wang X
    5. Zhou L
    6. Tong Y
    7. Ren R
    8. Leung KSM
    9. Lau EHY
    10. Wong JY
    11. Xing X
    12. Xiang N
    13. Wu Y
    14. Li C
    15. Chen Q
    16. Li D
    17. Liu T
    18. Zhao J
    19. Liu M
    20. Tu W
    21. Chen C
    22. Jin L
    23. Yang R
    24. Wang Q
    25. Zhou S
    26. Wang R
    27. Liu H
    28. Luo Y
    29. Liu Y
    30. Shao G
    31. Li H
    32. Tao Z
    33. Yang Y
    34. Deng Z
    35. Liu B
    36. Ma Z
    37. Zhang Y
    38. Shi G
    39. Lam TTY
    40. Wu JT
    41. Gao GF
    42. Cowling BJ
    43. Yang B
    44. Leung GM
    45. Feng Z

    (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

    The New England Journal of Medicine 382:1199–1207.

    https://doi.org/10.1056/NEJMoa2001316

    • PubMed
    • Google Scholar
27. 1. Maeda R
    2. Fujita J
    3. Konishi Y
    4. Kazuma Y
    5. Yamazaki H
    6. Anzai I
    7. Watanabe T
    8. Yamaguchi K
    9. Kasai K
    10. Nagata K
    11. Yamaoka Y
    12. Miyakawa K
    13. Ryo A
    14. Shirakawa K
    15. Sato K
    16. Makino F
    17. Matsuura Y
    18. Inoue T
    19. Imura A
    20. Namba K
    21. Takaori-Kondo A

    (2022) A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron

    Communications Biology 5:669.

    https://doi.org/10.1038/s42003-022-03630-3

    • PubMed
    • Google Scholar
28. 1. Ozono S
    2. Zhang Y
    3. Ode H
    4. Sano K
    5. Tan TS
    6. Imai K
    7. Miyoshi K
    8. Kishigami S
    9. Ueno T
    10. Iwatani Y
    11. Suzuki T
    12. Tokunaga K

    (2021) SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity

    Nature Communications 12:848.

    https://doi.org/10.1038/s41467-021-21118-2

    • PubMed
    • Google Scholar
29. 1. Peacock TP
    2. Goldhill DH
    3. Zhou J
    4. Baillon L
    5. Frise R
    6. Swann OC
    7. Kugathasan R
    8. Penn R
    9. Brown JC
    10. Sanchez-David RY
    11. Braga L
    12. Williamson MK
    13. Hassard JA
    14. Staller E
    15. Hanley B
    16. Osborn M
    17. Giacca M
    18. Davidson AD
    19. Matthews DA
    20. Barclay WS

    (2021) The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets

    Nature Microbiology 6:899–909.

    https://doi.org/10.1038/s41564-021-00908-w

    • PubMed
    • Google Scholar
30. 1. Peiris JSM
    2. Lai ST
    3. Poon LLM
    4. Guan Y
    5. Yam LYC
    6. Lim W
    7. Nicholls J
    8. Yee WKS
    9. Yan WW
    10. Cheung MT
    11. Cheng VCC
    12. Chan KH
    13. Tsang DNC
    14. Yung RWH
    15. Ng TK
    16. Yuen KY
    17. SARS study group

    (2003) Coronavirus as a possible cause of severe acute respiratory syndrome

    Lancet 361:1319–1325.

    https://doi.org/10.1016/s0140-6736(03)13077-2

    • PubMed
    • Google Scholar
31. 1. Peng G
    2. Yang Y
    3. Pasquarella JR
    4. Xu L
    5. Qian Z
    6. Holmes KV
    7. Li F

    (2017) Structural and molecular evidence suggesting coronavirus-driven evolution of mouse receptor

    The Journal of Biological Chemistry 292:2174–2181.

    https://doi.org/10.1074/jbc.M116.764266

    • PubMed
    • Google Scholar
32. 1. Punjani A
    2. Rubinstein JL
    3. Fleet DJ
    4. Brubaker MA

    (2017) cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

    Nature Methods 14:290–296.

    https://doi.org/10.1038/nmeth.4169

    • PubMed
    • Google Scholar
33. 1. Rohou A
    2. Grigorieff N

    (2015) CTFFIND4: Fast and accurate defocus estimation from electron micrographs

    Journal of Structural Biology 192:216–221.

    https://doi.org/10.1016/j.jsb.2015.08.008

    • PubMed
    • Google Scholar
34. 1. Rubinstein JL
    2. Brubaker MA

    (2015) Alignment of cryo-EM movies of individual particles by optimization of image translations

    Journal of Structural Biology 192:188–195.

    https://doi.org/10.1016/j.jsb.2015.08.007

    • PubMed
    • Google Scholar
35. 1. Scheid JF
    2. Barnes CO
    3. Eraslan B
    4. Hudak A
    5. Keeffe JR
    6. Cosimi LA
    7. Brown EM
    8. Muecksch F
    9. Weisblum Y
    10. Zhang S
    11. Delorey T
    12. Woolley AE
    13. Ghantous F
    14. Park SM
    15. Phillips D
    16. Tusi B
    17. Huey-Tubman KE
    18. Cohen AA
    19. Gnanapragasam PNP
    20. Rzasa K
    21. Hatziioanno T
    22. Durney MA
    23. Gu X
    24. Tada T
    25. Landau NR
    26. West AP
    27. Rozenblatt-Rosen O
    28. Seaman MS
    29. Baden LR
    30. Graham DB
    31. Deguine J
    32. Bieniasz PD
    33. Regev A
    34. Hung D
    35. Bjorkman PJ
    36. Xavier RJ

    (2021) B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV

    Cell 184:3205–3221.

    https://doi.org/10.1016/j.cell.2021.04.032

    • PubMed
    • Google Scholar
36. 1. Shang J
    2. Zheng Y
    3. Yang Y
    4. Liu C
    5. Geng Q
    6. Luo C
    7. Zhang W
    8. Li F

    (2018) Cryo-EM structure of infectious bronchitis coronavirus spike protein reveals structural and functional evolution of coronavirus spike proteins

    PLOS Pathogens 14:e1007009.

    https://doi.org/10.1371/journal.ppat.1007009

    • PubMed
    • Google Scholar
37. 1. Shang J
    2. Wan Y
    3. Liu C
    4. Yount B
    5. Gully K
    6. Yang Y
    7. Auerbach A
    8. Peng G
    9. Baric R
    10. Li F

    (2020a) Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry

    PLOS Pathogens 16:e1008392.

    https://doi.org/10.1371/journal.ppat.1008392

    • PubMed
    • Google Scholar
38. 1. Shang J
    2. Wan Y
    3. Luo C
    4. Ye G
    5. Geng Q
    6. Auerbach A
    7. Li F

    (2020b) Cell entry mechanisms of SARS-CoV-2

    PNAS 117:11727–11734.

    https://doi.org/10.1073/pnas.2003138117

    • PubMed
    • Google Scholar
39. 1. Shang J
    2. Ye G
    3. Shi K
    4. Wan Y
    5. Luo C
    6. Aihara H
    7. Geng Q
    8. Auerbach A
    9. Li F

    (2020c) Structural basis of receptor recognition by SARS-CoV-2

    Nature 581:221–224.

    https://doi.org/10.1038/s41586-020-2179-y

    • PubMed
    • Google Scholar
40. 1. Starr TN
    2. Czudnochowski N
    3. Liu Z
    4. Zatta F
    5. Park YJ
    6. Addetia A
    7. Pinto D
    8. Beltramello M
    9. Hernandez P
    10. Greaney AJ
    11. Marzi R
    12. Glass WG
    13. Zhang I
    14. Dingens AS
    15. Bowen JE
    16. Tortorici MA
    17. Walls AC
    18. Wojcechowskyj JA
    19. De Marco A
    20. Rosen LE
    21. Zhou J
    22. Montiel-Ruiz M
    23. Kaiser H
    24. Dillen JR
    25. Tucker H
    26. Bassi J
    27. Silacci-Fregni C
    28. Housley MP
    29. di Iulio J
    30. Lombardo G
    31. Agostini M
    32. Sprugasci N
    33. Culap K
    34. Jaconi S
    35. Meury M
    36. Dellota E
    37. Abdelnabi R
    38. Foo SYC
    39. Cameroni E
    40. Stumpf S
    41. Croll TI
    42. Nix JC
    43. Havenar-Daughton C
    44. Piccoli L
    45. Benigni F
    46. Neyts J
    47. Telenti A
    48. Lempp FA
    49. Pizzuto MS
    50. Chodera JD
    51. Hebner CM
    52. Virgin HW
    53. Whelan SPJ
    54. Veesler D
    55. Corti D
    56. Bloom JD
    57. Snell G

    (2021) SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

    Nature 597:97–102.

    https://doi.org/10.1038/s41586-021-03807-6

    • PubMed
    • Google Scholar
41. 1. Sztain T
    2. Ahn SH
    3. Bogetti AT
    4. Casalino L
    5. Goldsmith JA
    6. Seitz E
    7. McCool RS
    8. Kearns FL
    9. Acosta-Reyes F
    10. Maji S
    11. Mashayekhi G
    12. McCammon JA
    13. Ourmazd A
    14. Frank J
    15. McLellan JS
    16. Chong LT
    17. Amaro RE

    (2021) A glycan gate controls opening of the SARS-CoV-2 spike protein

    Nature Chemistry 13:963–968.

    https://doi.org/10.1038/s41557-021-00758-3

    • PubMed
    • Google Scholar
42. 1. Toelzer C
    2. Gupta K
    3. Yadav SKN
    4. Borucu U
    5. Davidson AD
    6. Kavanagh Williamson M
    7. Shoemark DK
    8. Garzoni F
    9. Staufer O
    10. Milligan R
    11. Capin J
    12. Mulholland AJ
    13. Spatz J
    14. Fitzgerald D
    15. Berger I
    16. Schaffitzel C

    (2020) Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein

    Science 370:725–730.

    https://doi.org/10.1126/science.abd3255

    • PubMed
    • Google Scholar
43. 1. van der Hoek L
    2. Pyrc K
    3. Jebbink MF
    4. Vermeulen-Oost W
    5. Berkhout RJM
    6. Wolthers KC
    7. Wertheim-van Dillen PME
    8. Kaandorp J
    9. Spaargaren J
    10. Berkhout B

    (2004) Identification of a new human coronavirus

    Nature Medicine 10:368–373.

    https://doi.org/10.1038/nm1024

    • PubMed
    • Google Scholar
44. 1. Walls AC
    2. Tortorici MA
    3. Frenz B
    4. Snijder J
    5. Li W
    6. Rey FA
    7. DiMaio F
    8. Bosch B-J
    9. Veesler D

    (2016) Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy

    Nature Structural & Molecular Biology 23:899–905.

    https://doi.org/10.1038/nsmb.3293

    • PubMed
    • Google Scholar
45. 1. Walls AC
    2. Park YJ
    3. Tortorici MA
    4. Wall A
    5. McGuire AT
    6. Veesler D

    (2020) Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

    Cell 181:281–292.

    https://doi.org/10.1016/j.cell.2020.02.058

    • Google Scholar
46. 1. Wan Y
    2. Shang J
    3. Graham R
    4. Baric RS
    5. Li F

    (2020a) Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus

    Journal of Virology 94:e00127-20.

    https://doi.org/10.1128/JVI.00127-20

    • PubMed
    • Google Scholar
47. 1. Wan Y
    2. Shang J
    3. Sun S
    4. Tai W
    5. Chen J
    6. Geng Q
    7. He L
    8. Chen Y
    9. Wu J
    10. Shi Z
    11. Zhou Y
    12. Du L
    13. Li F

    (2020b) Molecular mechanism for antibody-dependent enhancement of coronavirus entry

    Journal of Virology 94:e02015-19.

    https://doi.org/10.1128/JVI.02015-19

    • PubMed
    • Google Scholar
48. 1. Wölfel R
    2. Corman VM
    3. Guggemos W
    4. Seilmaier M
    5. Zange S
    6. Müller MA
    7. Niemeyer D
    8. Jones TC
    9. Vollmar P
    10. Rothe C
    11. Hoelscher M
    12. Bleicker T
    13. Brünink S
    14. Schneider J
    15. Ehmann R
    16. Zwirglmaier K
    17. Drosten C
    18. Wendtner C

    (2020) Virological assessment of hospitalized patients with COVID-2019

    Nature 581:465–469.

    https://doi.org/10.1038/s41586-020-2196-x

    • PubMed
    • Google Scholar
49. 1. Wrobel AG
    2. Benton DJ
    3. Xu P
    4. Roustan C
    5. Martin SR
    6. Rosenthal PB
    7. Skehel JJ
    8. Gamblin SJ

    (2020) Author Correction: SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects

    Nature Structural & Molecular Biology 27:1001.

    https://doi.org/10.1038/s41594-020-0509-2

    • PubMed
    • Google Scholar
50. 1. Wu K
    2. Li W
    3. Peng G
    4. Li F

    (2009) Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor

    PNAS 106:19970–19974.

    https://doi.org/10.1073/pnas.0908837106

    • PubMed
    • Google Scholar
51. Preprint

    1. Wu F
    2. Wang A
    3. Liu M
    4. Wang Q
    5. Chen J
    6. Xia S
    7. Ling Y
    8. Zhang Y
    9. Xun J
    10. Lu L
    11. Jiang S
    12. Lu H
    13. Wen Y
    14. Huang J

    (2020) Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications

    medRxiv.

    https://doi.org/10.2139/ssrn.3566211

    • Google Scholar
52. 1. Xiong X
    2. Qu K
    3. Ciazynska KA
    4. Hosmillo M
    5. Carter AP
    6. Ebrahimi S
    7. Ke Z
    8. Scheres SHW
    9. Bergamaschi L
    10. Grice GL
    11. Zhang Y
    12. CITIID-NIHR COVID-19 BioResource Collaboration
    13. Nathan JA
    14. Baker S
    15. James LC
    16. Baxendale HE
    17. Goodfellow I
    18. Doffinger R
    19. Briggs JAG

    (2020) A thermostable, closed SARS-CoV-2 spike protein trimer

    Nature Structural & Molecular Biology 27:934–941.

    https://doi.org/10.1038/s41594-020-0478-5

    • PubMed
    • Google Scholar
53. 1. Ye G
    2. Gallant J
    3. Zheng J
    4. Massey C
    5. Shi K
    6. Tai W
    7. Odle A
    8. Vickers M
    9. Shang J
    10. Wan Y
    11. Du L
    12. Aihara H
    13. Perlman S
    14. LeBeau A
    15. Li F

    (2021) The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates

    eLife 10:e64815.

    https://doi.org/10.7554/eLife.64815

    • PubMed
    • Google Scholar
54. 1. Ye G
    2. Liu B
    3. Li F

    (2022) Cryo-EM structure of a SARS-CoV-2 omicron spike protein ectodomain

    Nature Communications 13:1214.

    https://doi.org/10.1038/s41467-022-28882-9

    • PubMed
    • Google Scholar
55. 1. Ye G
    2. Pan R
    3. Bu F
    4. Zheng J
    5. Mendoza A
    6. Wen W
    7. Du L
    8. Spiller B
    9. Wadzinski BE
    10. Liu B
    11. Perlman S
    12. Li F

    (2023) Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19

    Journal of Virology 1:e0144823.

    https://doi.org/10.1128/jvi.01448-23

    • PubMed
    • Google Scholar
56. 1. Yurkovetskiy L
    2. Wang X
    3. Pascal KE
    4. Tomkins-Tinch C
    5. Nyalile TP
    6. Wang Y
    7. Baum A
    8. Diehl WE
    9. Dauphin A
    10. Carbone C
    11. Veinotte K
    12. Egri SB
    13. Schaffner SF
    14. Lemieux JE
    15. Munro JB
    16. Rafique A
    17. Barve A
    18. Sabeti PC
    19. Kyratsous CA
    20. Dudkina NV
    21. Shen K
    22. Luban J

    (2020) Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant

    Cell 183:739–751.

    https://doi.org/10.1016/j.cell.2020.09.032

    • PubMed
    • Google Scholar
57. 1. Zhang L
    2. Jackson CB
    3. Mou H
    4. Ojha A
    5. Peng H
    6. Quinlan BD
    7. Rangarajan ES
    8. Pan A
    9. Vanderheiden A
    10. Suthar MS
    11. Li W
    12. Izard T
    13. Rader C
    14. Farzan M
    15. Choe H

    (2020) SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

    Nature Communications 11:6013.

    https://doi.org/10.1038/s41467-020-19808-4

    • PubMed
    • Google Scholar
58. 1. Zhang W
    2. Shi K
    3. Geng Q
    4. Herbst M
    5. Wang M
    6. Huang L
    7. Bu F
    8. Liu B
    9. Aihara H
    10. Li F
    11. Gallagher T

    (2023) Structural evolution of SARS-CoV-2 omicron in human receptor recognition

    Journal of Virology 97:e0082223.

    https://doi.org/10.1128/jvi.00822-23

    • PubMed
    • Google Scholar
59. 1. Zhou F
    2. Yu T
    3. Du R
    4. Fan G
    5. Liu Y
    6. Liu Z
    7. Xiang J
    8. Wang Y
    9. Song B
    10. Gu X
    11. Guan L
    12. Wei Y
    13. Li H
    14. Wu X
    15. Xu J
    16. Tu S
    17. Zhang Y
    18. Chen H
    19. Cao B

    (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

    Lancet 395:1054–1062.

    https://doi.org/10.1016/S0140-6736(20)30566-3

    • PubMed
    • Google Scholar
60. 1. Zivanov J
    2. Nakane T
    3. Scheres SHW

    (2020) Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1

    IUCrJ 7:253–267.

    https://doi.org/10.1107/S2052252520000081

    • PubMed
    • Google Scholar

Author details

1. Qibin Geng

   1. Department of Pharmacology, University of Minnesota Medical School, Minneapolis, United States
   2. Center for Coronavirus Research, University of Minnesota, Minneapolis, United States

   Contribution

   Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Writing – review and editing

   Contributed equally with

   Yushun Wan

   Competing interests

   No competing interests declared

2. Yushun Wan

   1. Department of Pharmacology, University of Minnesota Medical School, Minneapolis, United States
   2. Center for Coronavirus Research, University of Minnesota, Minneapolis, United States

   Contribution

   Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Writing – review and editing

   Contributed equally with

   Qibin Geng

   Competing interests

   No competing interests declared

3. Fu-Chun Hsueh

   1. Department of Pharmacology, University of Minnesota Medical School, Minneapolis, United States
   2. Center for Coronavirus Research, University of Minnesota, Minneapolis, United States

   Contribution

   Data curation, Validation, Investigation, Writing – review and editing

   Competing interests

   No competing interests declared

4. Jian Shang

   1. Department of Pharmacology, University of Minnesota Medical School, Minneapolis, United States
   2. Center for Coronavirus Research, University of Minnesota, Minneapolis, United States

   Contribution

   Data curation, Formal analysis, Validation, Investigation, Writing – review and editing

   Competing interests

   No competing interests declared

5. Gang Ye

   1. Department of Pharmacology, University of Minnesota Medical School, Minneapolis, United States
   2. Center for Coronavirus Research, University of Minnesota, Minneapolis, United States

   Contribution

   Data curation, Formal analysis, Validation, Investigation, Writing – review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-6034-2174

6. Fan Bu

   1. Department of Pharmacology, University of Minnesota Medical School, Minneapolis, United States
   2. Center for Coronavirus Research, University of Minnesota, Minneapolis, United States

   Contribution

   Formal analysis, Validation, Visualization, Writing – review and editing

   Competing interests

   No competing interests declared

7. Morgan Herbst

   1. Department of Pharmacology, University of Minnesota Medical School, Minneapolis, United States
   2. Center for Coronavirus Research, University of Minnesota, Minneapolis, United States

   Contribution

   Data curation, Investigation, Writing – review and editing

   Competing interests

   No competing interests declared

8. Rowan Wilkens

   1. Department of Pharmacology, University of Minnesota Medical School, Minneapolis, United States
   2. Center for Coronavirus Research, University of Minnesota, Minneapolis, United States

   Contribution

   Data curation, Investigation, Writing – review and editing

   Competing interests

   No competing interests declared

9. Bin Liu

   Hormel Institute, University of Minnesota, Austin, United States

   Contribution

   Conceptualization, Resources, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Writing – review and editing

   For correspondence

   liu00794@umn.edu

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-6581-780X

10. Fang Li

    1. Department of Pharmacology, University of Minnesota Medical School, Minneapolis, United States
    2. Center for Coronavirus Research, University of Minnesota, Minneapolis, United States

    Contribution

    Conceptualization, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Writing – original draft, Project administration, Writing – review and editing

    For correspondence

    lifang@umn.edu

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0002-1958-366X

• 897

  views

• 136

  downloads

• 4

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.